The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence:

Van Osch, Frits; Jochems, Sylvia; Reulen, Raoul; Pirrie, Sarah; Nekeman, Duncan; Wesselius, Anke; James, Nicholas; Wallace, D Michael A; Cheng, Kar; van Schooten, Frederik J; Bryan, Richard; Zeegers, Maurice

DOI:
10.1007/s10552-018-1046-8

The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study

Frits H.M. van Osch* (1, 2), Sylvia H.J. Jochems (1, 2), Raoul C. Reulen (3), Sarah J. Pirrie (2), Duncan Nekeman (1, 2), Anke Wesselius (1), Nicholas D. James (2, 4), D. Michael A. Wallace (2, 4), KK Cheng (3), Frederik J. van Schooten (5), Richard T. Bryan (2), Maurice P. Zeegers (1, 2, 6)

1. Unit of Nutritional and Cancer Epidemiology, Chairgroup of Complex Genetics and Epidemiology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands
2. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
3. Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK
4. University Hospital Birmingham, NHS Foundation Trust, Birmingham, UK
5. Department of Pharmacology and Toxicology, School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands
6. Chairgroup of Complex Genetics and Epidemiology, Care and Public Health Research Institute (CAPRHI), Maastricht University, Maastricht, The Netherlands.

*Corresponding author. Frits H.M. van Osch, Department of Complex Genetics, PO Box 616, 6200 MD Maastricht, The Netherlands. ORCID ID: 0000-0003-4329-2560
Telephone: +3143 388 1991, e-mail: f.vanosch@maastrichtuniversity.nl

Acknowledgements:
We thank all the West Midlands Consultant Urologists and their units involved with the Bladder Cancer Prognosis Programme (BCPP), as well as the BCPP research nurses. The BCPP programme was funded by Cancer Research UK and supported by the Institute of Applied Health Research (IAHR) and the Institute of Cancer of Genomic Sciences, University of Birmingham. We would also like to thank Professor Lucinda Billingham's group and Dr. Ton Ambergen from the University of Birmingham and Maastricht University, respectively, for their advice regarding the statistical analyses.

Abstract

Background: Smoking is a major risk factor for bladder cancer, but the relationship between smoking cessation after initial treatment and bladder cancer recurrence has been investigated less frequently and not prospectively yet.

Methods: 722 non-muscle-invasive bladder cancer (NMIBC) patients (pTa, pT1 and CIS) from the prospective Bladder Cancer Prognosis Programme (BCPP) cohort, selected in the UK between 2005-2011, provided complete data on smoking behaviour before and up to 5 years after diagnosis. The impact of smoking behaviour on NMIBC recurrence was explored by multivariable Cox regression models investigating time-to-first NMIBC recurrence.

Results: Over a median follow-up period of 4.21 years, 403 pathologically confirmed NMIBC recurrences occurred in 210 patients. Only 25 current smokers at diagnosis quit smoking (14%) during follow-up and smoking cessation after diagnosis did not decrease risk of recurrence compared to continuing smokers (p=0.352).

Conclusions: Although quitting smoking after diagnosis might reduce the risk of recurrence based on retrospective evidence, this is not confirmed in this prospective study because the number of NMIBC patients quitting smoking before their first recurrence was too low. Nevertheless, this indicates an important role for urologists and other health care professionals in promoting smoking cessation in NMIBC.

Introduction

Bladder cancer (BC) is estimated to be the ninth most frequent cancer worldwide with approximately 400,000 newly diagnosed cases per year [1]. Compared to other cancers, mortality rates are generally lower for BC [1] since the majority of BCs diagnosed are non-muscle-invasive bladder cancers (NMIBC) [2]. However, NMIBC often recurs [3] and has a risk of progressing to muscle-invasive bladder cancer (MIBC) [4], events which impact on the quality of life of the patient [5] and generate high disease management costs [6].

Although smoking is an established risk factor for BC, its effects has been less frequently investigated in relation to BC prognosis [7–10]. Although many studies investigated effectiveness of treatment for NMIBC and MIBC with regard to recurrence, progression and mortality, most studies did not investigate the effect of smoking or other factors modifiable by patients on BC prognosis [11]. Nevertheless, the number of studies also reporting hazard ratios (HRs) for BC recurrence by smoking status at diagnosis has increased recently and the current body of evidence consistently shows that there is a small association between smoking and BC recurrence when comparing current smokers to never smokers at diagnosis [10,12]. However, the impact of smoking cessation after BC diagnosis on recurrence and mortality has not yet been quantified prospectively [13]. Studies have investigated the impact of smoking cessation within one year after diagnosis on BC recurrence, showing a slight decrease in risk of recurrence [14,15], and one study indicating no effect of quitting after diagnosis on overall or bladder cancer-specific mortality [16].

The Bladder Cancer Prognosis Programme (BCPP) followed-up BC patients for five years post-diagnosis and investigated changes in smoking behaviour in relation to the course of the disease [17]. The principal aim of this study was to investigate whether smoking cessation post-diagnosis and smoking behaviour pre-diagnosis influences BC recurrence.

Methods

The Bladder Cancer Prognosis programme

This study was conducted within the framework of the West Midlands Bladder Cancer Prognosis Programme (BCPP), a cohort study in the United Kingdom. Details of the study are described elsewhere [17]. In brief, individuals were included between December 2005 and October 2011 after referral to participating urology centres due to symptoms suspicious of BC and followed for a maximum of 5 years from diagnosis. Patients with previous cancer of the urethra, bladder, ureter, or renal pelvis within the last decade were excluded. The study was ethically-approved (06/MRE04/65) and all participants gave written informed consent.

Data collection

At or around time of diagnosis, trained research nurses used semi-structured face-to-face interviews and questionnaires to collect data on social support, health-related quality of life, sociodemographics, medical history, and health-related behaviours including smoking behaviour. Variables on smoking behaviour included current smoking status (never, former, current), duration (years of smoking), intensity (cigarettes per day), smoking cessation (in years) and tobacco type (filter, non-filter or rolled cigarettes, cigar or pipe). Monthly smoking status was also assessed retrospectively by postal questionnaires that were sent out to participants yearly until the end of follow-up.

Smoking status at diagnosis and during follow-up

A combined smoking status variable was created indicating continuing smokers, former smokers who consistently abstained, never smokers, former smokers who started smoking again, and current smokers who quit smoking post-diagnosis. Patients were considered quitters when they abstained consistently, so smokers who quit for 3 months and then started

again were considered as continuing smokers. Furthermore, for each participant that reported smoking cessation during follow-up it was confirmed whether this occurred before or after their first recurrence. If patients quit smoking after their first recurrence, they were considered as continuing smokers in the time-to-first recurrence analysis.

Population at risk

Of the 1,550 cases who agreed to participate, 231 were subsequently identified as not having BC. Patients who presented with MIBC (n=275) disease at diagnosis were excluded from analysis because they are fundamentally different from NMIBC with regard to recurrence. Patients with squamous or adeno-carcinomas of non-urothelial origin or with bladder cancer as secondary carcinoma were excluded (n=41). In addition to patients presenting with Ta and T1 tumours, carcinoma in situ (CIS) tumours were included (n=16) since they have an increased risk of recurrence [18]. In total, 846 (84%) of these patients had provided data on smoking behaviour at diagnosis and during follow-up and remained under follow-up within the cohort study. Of the included 846 NMIBC patients, there were 116 patients with unknown recurrent tumour stage. These 116 unconfirmed events were excluded for other analyses as well as 8 cases who had radiotherapy (on suspicion of being MIBC cases) resulting in a NMIBC patient population at risk of recurrence of 722.

No systematic guidance or tools were provided to enable patients to quit smoking after diagnosis, so care as usual was applied by all participating urologists.

Statistical analysis

BC recurrence was defined as a new tumour that was the same stage as the primary tumour (Ta or T1) but also when a primary Ta patient had a T1 recurrence. Patients that progressed from T1 to T2 disease were not counted as a recurrence but as a progression

event. Unfortunately, there were not enough events to also consider biological progression within this sample of NMIBC patients, as defined in the BCPP cohort [19]. Therefore, this study only focussed on confirmed recurrence events and patients who experienced a progression event were censored in the survival analysis when the progression event was diagnosed.

The impact of smoking behaviour on BC recurrence was explored by Cox regression models—with time since initial transurethral resection of the bladder tumour (TURBT) as the time-metric—investigating possible differences in likelihood of a first recurrence. We explored two different Cox regression models: one adjusted for age at diagnosis and sex (model 1) and one additionally adjusted for BC stage, grade, tumour size and number of tumours at diagnosis (model 2). This set of confounders was chosen since they are markers of NMIBC prognosis and are factors that contribute to European Association of Urology (EAU) risk stratification for clinical decisions[20]. Moreover, they are potentially associated with smoking behaviour at diagnosis [21]. Consequently, conditional risk set modelling was applied to investigate time between multiple recurrent events and analysis time was reset at each event [22]. For this analysis, reresection of tumours was added to model 2 as a confounder. The proportional hazards assumption was checked in all models using Schoenfeld residuals. Cumulative incidence functions (CIF) corrected for competing risks (death) were made [23].

Furthermore, the differences in mean number of recurrences over 5 years between never smokers, former smokers and continuing smokers were compared using a multivariable ANOVA model correcting for pairwise comparisons using Tukey's HSD. There were not enough BC-related death events (45) or confirmed progression events (19) to allow for separate analyses. A similarly low number of progression events has been observed in a large (n=718) NMIBC patient sample before [24].

NMIBC patients who died before the end of follow-up (n=157) were censored at time of death and patients who underwent cystectomy (n=15) were censored at the date of cystectomy (13). Other patients were considered lost to follow-up when the date on which patients were last seen in the hospital for bladder cancer-related therapy or the date on which they filled in their last follow-up questionnaire was before the end of follow-up (5 years).

Results

Number of recurrences and characteristics of population at risk

All 722 patients at risk of recurrence were followed over a median period of 4.21 years (IQR = 2.64-5.00 years). The majority of patients (506, 70%) were followed for at least 3 years. Over this period of follow-up, 210 NMIBC patients experienced at least one confirmed recurrence event. These 210 NMIBC patients accumulated a total of 403 confirmed recurrence events in the cohort.

Most cases were male (79%) and around the age of 70 (Table 1). Furthermore, continuing smokers seemed to be underrepresented in the low EAU risk group (12%), those who quit smoking seemed more likely to be younger and female, and continuing smokers seemed more likely to present with multiple tumours at diagnosis (Table 1). In the multivariate models, 26 patients were not included in the analysis due to missing data on age (n=7), number of tumours at diagnosis (n=15) and tumour size (n=4). Because participants were recruited from multiple centers, patients were treated by multiple urologists with different individual thresholds to perform certain therapies. Therefore, not all patients were treated exactly according to the EAU guidelines [20], which is often the case in actual clinical practice [25].

Table 1. Patient characteristics at diagnosis & number of recurrences over 5 years for 722 NMIBC patients treated with transurethral resection by smoking category.

	Overall (n=722)	Combined smoking status					
		Never smoker (n=103)	Former smoker (n=266)	Continuing Smoker (n=186)	Former smoker who started again (n=150)	Quitters after diagnosis (n=17)	p-value*
Age in years							<0.001
Median (25th-75th percentile)	71 (63-77)	72 (61-79)	72 (67-79)	67 (57-74)	72 (64-77)	62 (56-67)	
Sex							<0.001
Male	573 (79%)	63 (61%)	231 (87%)	139 (75%)	129 (86%)	11 (65%)	
Female	149 (21%)	40 (39%)	35 (13%)	47 (25%)	21 (14%)	6 (35%)	
EAU risk group							<0.001
Low	128 (18%)	28 (27%)	71 (27%)	23 (12%)	4 (3%)	2 (12%)	
Intermediate	383(53%)	50 (49%)	131 (49%)	97 (52%)	91 (61%)	14 (82%)	
High	211 (29%)	25 (24%)	64 (24%)	66 (36%)	55 (37%)	1 (6%)	
Number of tumours							<0.001
1	429 (61%)	70 (70%)	179 (69%)	100 (55%)	69 (46%)	11 (65%)	
2-7	258 (36%)	27 (27%)	74 (28%)	76 (42%)	75 (50%)	6 (35%)	
>=8	22 (3%)	3 (3%)	8 (3%)	6 (3%)	5 (3%)	0 (-)	
Tumour size							0.068
<3cm	445 (63%)	68 (68%)	174 (67%)	105 (58%)	85 (57%)	13 (76%)	
>=3cm	260 (37%)	32 (32%)	84 (33%)	77 (42%)	63 (43%)	4 (24%)	
Grade							0.001
1	212 (30%)	34 (34%)	99 (38%)	51 (28%)	26 (17%)	2 (13%)	
2	257 (36%)	34 (34%)	75 (28%)	73 (40%)	66 (44%)	9 (56%)	
3	245 (34%)	33 (33%)	90 (34%)	60 (32%)	57 (38%)	5 (31%)	
Stage							0.590
pTa	476 (66%)	68 (66%)	184 (69%)	115 (62%)	95 (63%)	14 (82%)	
pT1	239 (33%)	35 (34%)	79 (30%)	69 (37%)	53 (35%)	3 (18%)	
pCis	7 (1%)	0 (-)	3 (1%)	2 (1%)	2 (1%)	0 (-)	
No of recurrences							0.337
1	108 (51%)	18 (62%)	28 (46%)	33 (53%)	27 (52%)	2 (33%)	
2	46 (22%)	6 (21%)	16 (26%)	16 (26%)	6 (11%)	2 (33%)	
>3	56 (27%)	5 (17%)	17 (28%)	13 (21%)	19 (37%)	2 (33%)	
Smoking intensity							0.076
1-9 cigarettes	128 (29%)	NA	55 (30%)	23 (21%)	42 (34%)	8 (50%)	
10-19 cigarettes	140 (32%)	NA	53 (28%)	42 (38%)	42 (34%)	3 (19%)	
>20 cigarettes	167 (38%)	NA	78 (42%)	45 (41%)	39 (32%)	5 (31%)	
Smoking duration							<0.001
1-9 years	45 (10%)	NA	26 (14%)	2 (2%)	16(14%)	1 (6%)	
10-19 years	83 (19%)	NA	43 (23%)	10 (9%)	29 (25%)	1 (6%)	
20-29 years	87 (20%)	NA	46 (25%)	12 (11%)	27 (23%)	2 (13%)	
30-39 years	88 (21%)	NA	37 (20%)	28 (25%)	19 (16%)	4 (25%)	
>40 years	127 (30%)	NA	32 (17%)	60 (54%)	27 (23%)	8 (50%)	
Smoking cessation							0.051
<20 years	48 (12%)	NA	23 (9%)	NA	25 (17%)	NA	
21-40 years	208 (51%)	NA	134 (51%)	NA	74 (49%)	NA	
>40 years	155 (38%)	NA	104 (40%)	NA	51 (34%)	NA	

*Kruskal-Wallis test for continuous and chi-square test for categorical variables

Associations between smoking behaviour pre and post-diagnosis and BC recurrence

Although HR estimates for smoking cessation pre-diagnosis indicated a protective association with BC recurrence, the p for linear trend was not statistically significant (p_{trend}=0.126) and therefore the association cannot be considered as strong (Table 2). No association between smoking status and risk of recurrence was observed in the multivariable model (Table 2). Interestingly, when compared to continuing smokers (HR=1.04, 95% CI=0.65-1.66) HRs were similar for those who quit smoking (p=0.352) and former smokers who started again post-diagnosis (p=0.431) (Table 2). Additionally, the cumulative incidence function shows that cumulative incidence of BC recurrence was lowest for former smokers and never smokers (Figure 1).

Insert Figure 1 here

Figure 1. Cumulative incidence functions with correction for competing risk (death) indicating cumulative incidence of first recurrence per category of smoking status in NMIBC patients treated with TURBT.

Only 25 smokers (14%) of the 174 current smokers originally recorded at diagnosis quit smoking at any point during follow-up. Three quitters were excluded for full analysis for not having information on their date last seen and another five had missing data regarding the invasiveness of their recurrent events. Of the 480 former smokers at diagnosis, 172 (36%) started smoking (any form of tobacco) again post-diagnosis in all included 846 NMIBC patients.

166 Exposure to environmental tobacco smoke during childhood (HR=1.17, 95%CI=0.81-
167 1.68) or adulthood (HR=1.02, 95%CI=0.76-1.36) did not seem to have any impact on time to
168 first recurrence (Table 2).

Table 2. Cox regression analysis investigating the association between combined smoking status, smoking cessation before diagnosis and passive smoking and time-to-first recurrence in NMIBC patients treated with TURBT.

	Age & sex adjusted			Multivariable model*		
	HR	**95% CI**	**number of events / patients at risk**	**HR**	**95% CI**	**number of events / patients at risk**
Combined smoking status						
Never smoker	1.00	ref	29/103	1.00	ref	28/99
Former smoker	0.79	0.51-1.24	61/266	0.78	0.48-1.24	59/254
Continuing smoker	1.17	0.75-1.83	62/186	1.04	0.65-1.66	61/180
Former smoker who started again**	1.04	0.65-1.64	51/150	0.87	0.53-1.41	49/146
Current smoker who quit smoking***	1.25	0.52-3.00	6/17	1.47	0.63-3.41	6/17
Smoking cessation (in years) ****						
<20 years	0.81	0.46-1.43	15/48	0.82	0.46-1.46	15/47
21-40 years	0.76	0.53-1.08	57/208	0.74	0.51-1.08	54/200
>40 years	0.67	0.44-1.02	39/155	0.71	0.46-1.09	38/148
p for trend	0.070			0.126		
Exposed to passive smoking during childhood?						
No	1.00	ref	36/142	1.00	ref	35/138
Yes	1.23	0.86-1.75	173/576	1.17	0.81-1.68	168/554
Exposed to passive smoking during adulthood?						
No	1.00	ref	74/261	1.00	ref	74/261
Yes	1.03	0.77-1.38	135/454	1.02	0.76-1.36	135/454

* All estimates adjusted for age, sex, stage, grade, tumour size and number of tumours

** Former smoker who started again and current smoker who quit smoking not included in former smokers at diagnosis

*** Smokers who quit after their first event are considered as current smokers

**** Reference category = current smokers at diagnosis, estimates also include former smokers who started again after diagnosis

Table 3 shows HRs for time to first recurrence by smoking intensity, duration and pack-years. No linear trends were observed although the highest categories showed the highest point estimates for both smoking intensity and pack years. For smoking duration the HRs were divergent and did not indicate any trend (p_{trend}=0.729) at all.

177 **Table 3. Multivariable Cox regression analysis concerning the association between**
178 **smoking pack-years, intensity and duration (recorded at diagnosis) with time to first**
179 **recurrence in NMIBC patients treated with TURBT.**
180

	Age & sex adjusted			Multivariable model*		
	HR	**95% CI**	**number of events / patients at risk**	**HR**	**95% CI**	**number of events / patients at risk**
Never smoker	1.00	ref	29/103	1.00	ref	28/99
Pack-years						
1-9 packyears	0.86	0.53-1.42	36/141	0.81	0.48-1.37	34/134
10-19 packyears	0.95	0.54-1.67	22/81	0.92	0.51-1.65	22/80
20-29 packyears	0.93	0.49-1.77	15/58	0.81	0.42-1.60	15/57
30-39 packyears	0.70	0.35-1.43	11/55	0.60	0.30-1.22	11/53
>40 packyears	1.28	0.76-2.14	30/86	1.14	0.66-1.97	29/83
p for trend	0.365			0.688		
Smoking intensity (cigarettes/day)						
1-9 cigarettes	0.83	0.50-1.38	32/128	0.81	0.47-1.38	30/122
10-19 cigarettes	0.75	0.45-1.28	31/140	0.61	0.35-1.07	31/138
20+ cigarettes	1.24	0.79-1.96	55/167	1.16	0.72-1.85	54/160
p for trend	0.112			0.198		
Smoking duration (in years)						
1-9 years	1.03	0.52-2.05	12/45	0.97	0.48-1.95	12/43
10-19 years	0.94	0.54-1.62	22/83	0.85	0.48-1.50	21/78
20-29 years	0.79	0.45-1.39	21/87	0.79	0.44-1.44	20/85
30-39 years	1.08	0.61-1.89	26/88	0.93	0.52-1.66	25/85
40+ years	1.00	0.60-1.64	36/127	0.88	0.52-1.49	36/124
p for trend	0.917			0.729		

* All estimates adjusted for age, sex, stage, grade, tumour size and number of tumours at diagnosis
181

When considering multiple events that have occurred in patients (Table 4) the HRs are similar to the time to first recurrence analysis (HR for continuing vs never smokers is 1.10, 95%CI=0.72-1.69). However, continuing smokers seemed to have experienced more recurrences than never smokers on average over 5 years on average, however not significantly (0.64 vs 0.45, p=0.308).

Table 4. Conditional risk set model investigating time between multiple recurrence events in NMIBC patients treated with TURBT by smoking status at diagnosis and after diagnosis.

	HR*	95% CI	number of events / patients at risk	Mean number of recurrences over 5 years (95% CI)
Smoking status				
Never smoker	1.00	ref	43/99	0.45 (0.28-0.63)
Former smoker	0.71	0.47-1.08	108/254	0.45 (0.33-0.57)
Continuing smoker	1.10	0.72-1.69	116/180	0.64 (0.47-0.81)
Former smoker who started again	0.89	0.56-1.43	108/146	0.82 (0.57-1.06)
Current smoker who quit smoking**	0.85	0.35-2.04	18/19	0.84 (0.10-1.58)

* All estimates adjusted for age, sex, stage, grade, tumour size, number of tumours and reresection of recurrent tumour

** Smokers who have quit after their first event (n=2) are also included

Discussion

Smoking cessation post-diagnosis and BC recurrence & clinical implications

The reported HRs give reason to believe that quitting smoking does not influence the likelihood of NMIBC recurrence over 5 years when compared to continuing smokers in our sample. However, the number of quitters in our prospective sample was small which complicates drawing conclusions for this group. Another (retrospective) patient cohort study which assessed smoking cessation post-diagnosis concluded that quitting smoking significantly reduced risk of recurrence (HR=0.45, 95% CI=0.25-0.83, comparing quitters to continuing smokers), however the proportion of quitters (~43% of current smokers at diagnosis) was also considerably larger [14]. In another retrospective cohort study, Fleshner et al concluded that it remained unclear whether smoking cessation at time of diagnosis is beneficial with regard to BC recurrence [15] although Aveyard et al. estimated that the Fleshner study shows a HR of 0.71 (95% CI=0.48-1.05) when comparing quitters to continuing smokers[26], which is similar to the estimate observed in the study by Chen et al. Taken together, the limited evidence at this point seems to indicate that quitting smoking at or closely after diagnosis could reduce risk of recurrence. However, even across several smoking-related cancer sites such as lung cancer where this association is stronger, evidence to imply a strong, causal relationship between smoking behaviour after diagnosis and recurrence is still limited [27] so more prospective research is needed.

Considering the prolonged latency period for the development of BC after exposures [2], it is credible that the association between altering smoking behaviour post-diagnosis and likelihood of a first recurrence or multiple recurrences over 5 years is not as strong as the association between smoking and carcinogenesis. Similarly, epidemiological evidence suggests that pre-diagnostic smoking cessation does not immediately lower the risk of BC [28], also indicating a longer latency period than 5 years. Furthermore, it is considered that a

first BC recurrence is often the result of incomplete resection and/or tumour cell re-implantation, and that genuine new tumour formation only plays a more important role in later recurrences [29]. It is therefore reasonable to suggest that, because of the DNA-damaging effects of cigarette smoke [30], modifying smoking behaviour may only influence later recurrences and possibly those that may occur beyond the follow-up period of 5 years reported here.

Notwithstanding the results from our study, when considering the impact of comorbidities on overall survival in BC patients [31] which include several smoking-related diseases [32] and other evidence indicating beneficial and significant results of post-diagnostic smoking cessation in retrospective studies [14,15], it is evident that smoking cessation should be encouraged for NMIBC patients at diagnosis.

It is striking that only 14% of current smokers at diagnosis in our sample quit smoking post-diagnosis. There are examples of succesful smoking cessation interventions in urology [33], and several studies found that when patients were diagnosed with BC they were more likely to quit smoking [34,35]. Therefore, urologists should continue to improve smoking cessation counselling in newly diagnosed NMIBC patients and to be current on the available tools to improve smoking cessation figures. Moreover, more intervention clinical research investigating smoking cessation programmes in NMIBC patients is warranted.

Smoking behaviour pre-diagnosis & exposure to environmental tobacco smoke

Smoking cessation was most beneficial, with regard to reducing the risk of recurrence, the longer before diagnosis it happened compared to continuing smokers. This was the strongest association observed in our study and has been observed in other studies as well, although not consistently [12]. Other results were in line with earlier studies investigating smoking status

241 at diagnosis and BC recurrence as well, by indicating a slightly increased risk of recurrence
242 in NMIBC patients for current smokers compared to never smokers in a meta-analysis [10].

243 Another recent study not included in the aforementioned meta-analysis shows similar
244 HRs (HR=1.49, 95%C.I.=0.95-2.33) for current smokers at diagnosis [8]. However, when
245 including this study and our study (data from continuing smokers) in the meta-analysis the
246 pooled HR barely changes from 1.27 (95%CI=1.09-1.46) to 1.26 (95% CI= 1.12-1.40) [10],
247 indicating a significantly increased risk of recurrence for current smokers at diagnosis
248 compared to never smokers. Possibly, the lack of association for continuing smokers in this
249 study can be explained through multiple synchronous tumours being present at diagnosis in
250 epithelial tumours. This theory of “field cancerization” proposes that (pre-)malignant
251 transformation of cells has already occurred at different sites across the urothelium,
252 explaining why (changing) smoking exposure will not have a large impact on disease
253 prognosis [36].

254 Additonally, given that recent reviews indicate no considerable heterogeneity between
255 studies that do not show an association between environmental tobacco smoke and risk of
256 BC, it is unlikely that we would have shown any substantial association with BC recurrence
257 either [37,38].

258 Because no substantial association between smoking status pre-diagnosis and BC
259 recurrence was observed in adjusted models it is possible that the tumour characteristics
260 associated with BC recurrence (stage, grade, tumour size, number of tumours) included as
261 confounders in these models overshadow the effects of smoking behaviour in determining
262 risk of BC recurrence [21] and possible also mortality since no association between quitting
263 smoking after diagnosis and all-cause or bladder-cancer-speficic mortality was observed in a
264 large retrospective cohort study[16]. Moreover, since current smokers at diagnosis in our
265 cohort have been associated with having a higher stage, higher grade and larger tumour size

compared to never smokers [39], smoking behaviour might play a more crucial role in determining risk of recurrence already before diagnosis through promoting unfavourable tumour characteristics associated with BC recurrence at diagnosis, although in a Dutch cohort of 323 UBC patients there was only a weak association between smoking intensity and increased risk of a more aggressive tumour type [40].

Strengths and weaknesses

Despite the prospective nature of our study there were some limitations restricting the analyses. Due to the relatively short follow-up of this study, long term effects of smoking cessation post-diagnosis could not be assessed and the number of deaths due to BC in the NMIBC patients within our cohort was too low for Cox regression analysis. Also, it was not possible to obtain detailed information on adjuvant therapy for all patients, so differences in adjuvant therapy could not be considered in the statistical analysis. Additionally, we did not correct for biomarkers of BC recurrence such as mutations in the *FGFR3* or *TP53* genes [41], although they might work together with smoking intensity in predicting BC outcome [42].

Furthermore, one of the caviats of using only self-reported questionnaire data to assess smoking exposure was likely demonstrated in our sample of NMIBC patients. The large proportion (about 1 in 3) of former smokers pre-diagnosis who reported to have started smoking again post-diagnosis is implausible and is probably observed due to misclassification of either the questionnaire at baseline or during follow-up. A high misclassification rate (47%) when comparing self-reported data on smoking behaviour to cotinine values in blood was also shown in another sample of bladder cancer patients undergoing surveillance [43]. Preferably, future studies should consider more reliable ways of verifying smoking exposure through biochemical analysis.

290 Unfortunately, at the start of the study we did not anticipate this small proportion of
291 quitters after diagnosis which is why the analysis concerning quitters is underpowered.

Conclusion

Although quitting smoking after diagnosis might reduce probability of recurrence based on retrospective evidence, the number of NMIBC patients quitting smoking in our prospective study was low. This indicates an important role for urologists and other health care professionals in promoting smoking cessation in NMIBC. Based on the current evidence, smoking cessation pre-diagnosis seems to have the largest impact on reducing risk of recurrence after NMIBC diagnosis.

References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71: 96–108. doi:10.1016/j.eururo.2016.06.010
2. Bryan RT, Zeegers MP, van Roekel EH, Bird D, Grant MR, Dunn JA, et al. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU Int. 2013;112: 169–175. doi:10.1111/bju.12032
3. Yan Y, Andriole GL, Humphrey PA, Kibel AS. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer. Wiley Subscription Services, Inc., A Wiley Company; 2002;95: 1239–1246. doi:10.1002/cncr.10822
4. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 374: 239–249. doi:http://dx.doi.org/10.1016/S0140-6736(09)60491-8
5. Roychowdhury DF, Hayden A, Liepa AM. Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol. 2003;21: 673–678.
6. Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. Eur Urol. 2014;66: 253–262. doi:10.1016/j.eururo.2014.01.006
7. Hou L, Hong X, Dai M, Chen P, Zhao H, Wei Q, et al. Association of smoking status with prognosis in bladder cancer: A meta-analysis. Oncotarget. Impact Journals; 2016;5. doi:10.18632/oncotarget.13606
8. Li HM, Azhati B, Rexiati M, Wang WG, Li XD, Liu Q, et al. Impact of smoking status and cumulative smoking exposure on tumor recurrence of non-muscle-invasive bladder cancer. Int Urol Nephrol. 2016; doi:10.1007/s11255-016-1441-6
9. Wilcox AN, Silverman DT, Friesen MC, Locke SJ, Russ DE, Hyun N, et al. Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project. Cancer Causes Control. Springer International Publishing; 2016;27: 1429–1435. doi:10.1007/s10552-016-0821-7
10. van Osch FHM, Jochems SHJ, van Schooten FJ, Bryan RT, Zeegers MP. Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. J Urol. 2016;195: 872–879. doi:10.1016/j.juro.2015.10.139
11. Gritz ER, Dresler C, Sarna L. Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious. Cancer Epidemiol Biomarkers Prev. 2005;14: 2287–93. doi:10.1158/1055-9965.EPI-05-0224
12. Simonis K, Shariat SF, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Curr Opin Urol. 2014;24: 492–499.
13. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. Eur Urol. 2014;65: 742–754. doi:10.1016/j.eururo.2013.06.010
14. Chen C-H, Shun C-T, Huang K-H, Huang C-Y, Tsai Y-C, Yu H-J, et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. doi:10.1111/j.1464-410X.2007.06873.x
15. Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, et al. Influence of Smoking Status on the Disease-Related Outcomes of Patients with Tobacco-Associated Superficial Transitional Cell Carcinoma of the Bladder. 1998;
16. Koshiaris C, Aveyard P, Oke J, Ryan R, Szatkowski L, Stevens R, et al. Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort

study. Br J Cancer. Nature Publishing Group; 2017;117: 1224–1232. doi:10.1038/bjc.2017.179

17. Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, et al. The West Midlands Bladder cancer prognosis programme: Rationale and design. BJU Int. 2010;105: 784–788. doi:10.1111/j.1464-410X.2009.08849.x
18. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur Urol. 2006;49: 466–477. doi:10.1016/j.eururo.2005.12.031
19. Bryan RT, Cheng KK, James ND, Zeegers MP, Wallace DMA. Re: Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition: D. Lamm, R. Persad, M. Brausi, R. Buckley, J. A. Witjes, J. Palou, A. Böhle, A. M. Kamat, M. Colombel and M. Soloway J Urol 2014; 191: 20–27. [Internet]. The Journal of Urology. 2014. pp. 1930–1931. doi:10.1016/j.juro.2014.01.011
20. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [Internet]. European Urology. 2017. doi:10.1016/j.eururo.2016.05.041
21. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Actas Urológicas Españolas (English Ed. 2012;36: 389–402.
22. Amorim LDAF, Cai J. Modelling recurrent events: A tutorial for analysis in epidemiology. Int J Epidemiol. 2015;44: 324–333. doi:10.1093/ije/dyu222
23. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66: 648–653. doi:10.1016/j.jclinepi.2012.09.017
24. Lammers RJM, Witjes WPJ, Hendricksen K, Caris CTM, Janzing-Pastors MHC, Witjes JA. Smoking Status Is a Risk Factor for Recurrence After Transurethral Resection of Non–Muscle-Invasive Bladder Cancer. Eur Urol. 2011;60: 713–720. doi:10.1016/j.eururo.2011.07.010
25. Hendricksen K, Aziz A, Bes P, Chun FK-H, Dobruch J, Kluth LA, et al. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non–muscle-invasive Bladder Cancer: Results of a European Survey. Eur Urol Focus. 2017; doi:10.1016/j.euf.2017.09.002
26. Aveyard P, Adab P, Cheng KK, Wallace DMA, Hey K, Murphy MFG. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. Wiley/Blackwell (10.1111); 2002;90: 228–239. doi:10.1046/j.1464-410X.2002.02880.x
27. Warren GW, Sobus S, Gritz ER. The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol. 2014;15: e568-80. doi:10.1016/S1470-2045(14)70266-9
28. van Osch FH, Jochems SH, van Schooten F-J, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol. 2016;45: 857–870. doi:10.1093/ije/dyw044
29. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng K, Wallace DMA, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl. The Royal College of Surgeons of England ; 2010;92: 519–524. doi:10.1308/003588410X12664192076935

30. Corral R, Lewinger JP, Van Den Berg D, Joshi AD, Yuan J-M, Gago-Dominguez M, et al. Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int J Cancer. 2014;135: 335–347. doi:10.1002/ijc.28693
31. Megwalu II, Vlahiotis A, Radwan M, Piccirillo JF, Kibel AS. Prognostic Impact of Comorbidity in Patients with Bladder Cancer. Eur Urol. 2008;53: 581–589. doi:10.1016/j.eururo.2007.10.069
32. Piccirillo JF, Tierney RM, Costas I, Grove L, Edward L. Spitznagel J, AR F, et al. Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry. JAMA. American Medical Association; 2004;291: 2441. doi:10.1001/jama.291.20.2441
33. Bjurlin MA, Cohn MR, Kim DY, Freeman VL, Lombardo L, Hurley SD, et al. Brief Smoking Cessation Intervention: A Prospective Trial in the Urology Setting. J Urol. 2013;189: 1843–1849. doi:10.1016/j.juro.2012.11.075
34. Bassett JC, Gore JL, Chi AC, Kwan L, McCarthy W, Chamie K, et al. Impact of a bladder cancer diagnosis on smoking behavior. J Clin Oncol. 2012;30: 1871–8. doi:10.1200/JCO.2011.36.6518
35. Ostroff J, Garland J, Moadel A, Fleshner N, Hay J, Cramer L, et al. Cigarette smoking patterns in patients after treatment of bladder cancer. J Cancer Educ. 2000;15: 86–90. doi:10.1080/08858190009528663
36. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63: 1727–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/12702551
37. Osch F van, Jochems S, Wesselius A, Schooten F van, Bryan R, Zeegers M. A Stratified Meta-Analysis of the Association between Exposure to Environmental Tobacco Smoke during Childhood and Adulthood and Urothelial Bladder Cancer Risk. Int J Environ Res Public Heal 2018, Vol 15, Page 569. Multidisciplinary Digital Publishing Institute; 2018;15: 569. doi:10.3390/IJERPH15040569
38. Lee PN, Thornton AJ, Hamling JS, Lee PN. Epidemiological evidence on environmental tobacco smoke and cancers other than lung or breast. Regul Toxicol Pharmacol. 2016;80: 134–163. doi:10.1016/j.yrtph.2016.06.012
39. van Roekel EH, Cheng KK, James ND, Wallace DMA, Billingham LJ, Murray PG, et al. Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumors at diagnosis. Int J Cancer. 2013;133: 446–454. doi:10.1002/ijc.28017
40. Barbosa ALA, Vermeulen SHHM, Aben KK, Grotenhuis AJ, Vrieling A, Kiemeney LA. Smoking intensity and bladder cancer aggressiveness at diagnosis. Real FX, editor. PLoS One. Public Library of Science; 2018;13: e0194039. doi:10.1371/journal.pone.0194039
41. Bryan RT, Zeegers MP, James ND, Wallace DMA, Cheng KK. Biomarkers in bladder cancer. BJU Int. Blackwell Publishing Ltd; 2010;105: 608–613. doi:10.1111/j.1464-410X.2009.08880.x
42. Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi S-R, et al. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome. Cancer. Wiley Subscription Services, Inc., A Wiley Company; 2013;119: 756–765. doi:10.1002/cncr.27763
43. Thong AE, Petruzella S, Orlow I, Zabor EC, Ehdaie B, Ostroff JS, et al. Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. Eur Urol Focus. Elsevier; 2016;2: 441–444. doi:10.1016/j.euf.2015.12.002